Presentations & Publications
IGM-8444 is a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile
ASCO20 Virtual Scientific Program – May 29-31, 2020
Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile
AACR Virtual Meeting II – June 22 – 24, 2020 Poster Session: Antibody Technologies – Experimental and Molecular Therapeutics Abstract: 518 / 2, E-Poster: June 22, 2020, 9:00…
A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release
AACR Virtual Meeting II – June 22 – 24, 2020 Session: Therapeutics Antibodies 4 – Immunology Abstract: 5664 / 25 E-Poster: June 22, 2020, 9:00 AM – 6:00…
IGM-8444 as a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile.
ASCO20 Virtual Scientific Program – May 29-31, 2020 Poster Session: Developmental Therapeutics–Molecularly Targeted Agents and Tumor Biology Abstract # 3595
Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323)
ASCO20 Virtual Scientific Program – May 29-31, 2020 Session: Developmental Therapeutics–Immunotherapy Abstract # e15007
IGM-2323: High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release
American Society of Hematology Annual Meeting, Orlando, FL – December 7-10, 2019
Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies
PEGS Europe – November, 2019
Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo
AACR Annual Meeting – April 1-5, 2017
- « Previous
- 1
- 2
- 3
- 4
- Next »